TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7844011

Group type: EXPERIMENTAL
Intervention: Lead weights (0.8 to 2.0 g) glued to the upper lid with adhesive (Combihesive* or Tesafix)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hour-glass dressing
Number of subjects: 48
Study: 3041973

Group type: EXPERIMENTAL
Intervention: Combination homeopathic preparation (Gripp-Heel)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 170
Study: 31493775

Group type: EXPERIMENTAL
Intervention: KC for 60 min daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: KC for 120 min daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional care (controls)
Number of subjects: 120
Study: 30482739

Group type: EXPERIMENTAL
Intervention: Web-based telemanagement system (TECCU)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nurse-assisted telephone care (G_NT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard care (G_control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All groups (TECCU, G_NT, G_control)
Number of subjects: 63
Study: 26563336

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 143

Group type: COMPARATOR
Intervention: Phase SD
Number of subjects: 143
Study: 26196695

Group type: EXPERIMENTAL
Intervention: Linezolid (600-mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No vasopressor receipt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal renal function (eGFR 30-80 vs >80)
Number of subjects: 0
Study: 23630950

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg QD for 12 weeks
Number of subjects: 171

Group type: COMPARATOR
Intervention: Telmisartan 80 mg QD for 12 weeks
Number of subjects: 171
Study: 20072091

Group type: EXPERIMENTAL
Intervention: Hextend (15 mL/kg administered during surgery)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Voluven (15 mL/kg administered during surgery)
Number of subjects: 54
Study: 18230238

Group type: EXPERIMENTAL
Intervention: Expressive writing (writing about their traumatic experience)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (writing about time management)
Number of subjects: 25
Study: 16997114

Group type: EXPERIMENTAL
Intervention: Amlexanox oral adhesive tablets applied 4 times a day for 5 days
Number of subjects: 212

Group type: COMPARATOR
Intervention: Vehicle-control
Number of subjects: 212
Study: 12235719

Group type: EXPERIMENTAL
Intervention: Echocardiographic screening
Number of subjects: 9697

Group type: COMPARATOR
Intervention: Clinical assessment alone (Control)
Number of subjects: 9697
Study: 10232632

Group type: EXPERIMENTAL
Intervention: Exercise at 50% of maximal oxygen consumption followed by a milk shake intake
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary activities for 61 hours
Number of subjects: 8
Study: 7790244

Group type: EXPERIMENTAL
Intervention: Fast-neutron radiotherapy (20.4 Gy/12 fractions/4 weeks)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Conventional photon therapy (70 Gy/35 fractions/7 weeks)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Fast-neutron radiotherapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Conventional photon therapy
Number of subjects: 169
Study: 2192184

Group type: EXPERIMENTAL
Intervention: Cepharanthin
Number of subjects: 94

Group type: COMPARATOR
Intervention: S‐Adchnon (adrenochrome derivative)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Hythiol (L‐cysteine)
Number of subjects: 94
Study: 393182

Group type: EXPERIMENTAL
Intervention: Combination of cimetidine (H2 antagonist) and chlorpheniramine (H1 antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chlorpheniramine (H1 antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cimetidine (H2 antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6353233

Group type: EXPERIMENTAL
Intervention: semustine (methyl‐CCNU)
Number of subjects: 3633

Group type: COMPARATOR
Intervention: other therapies
Number of subjects: 3633
Study: 30636547

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 1294
Study: 30215466

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (4 mg, 5 min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine (25 mg, 25 min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ringer (500 ml, 20 min)
Number of subjects: 90
Study: 26579834

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1160
Study: 24126180

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear stem cells
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 18
Study: 22408779

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate discontinued after 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate administered after osseointegration for 6 months
Number of subjects: 0
Study: 19409337

Group type: EXPERIMENTAL
Intervention: FR-2 appliance of Fränkel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated Class II control group
Number of subjects: 30
Study: 16934332

Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study: 15845179

Group type: COMPARATOR
Intervention: Continuous thoracic radiation therapy (50 Gy delivered in 2.0-Gy fractions over 5 weeks)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Interdigitating split-course thoracic radiation therapy (50 Gy delivered in 2.5-Gy fractions over 8 weeks)
Number of subjects: 110
Study: 12120883

Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate acetylcysteinate (TGA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiamphenicol glycinate (TG)
Number of subjects: 0
Study: 10630349

Group type: EXPERIMENTAL
Intervention: Herbal treatment prescribed by traditional healers
Number of subjects: 306

Group type: COMPARATOR
Intervention: Symptomatic treatment or acyclovir (Control)
Number of subjects: 306
Study: 7790606

Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CPAP (5 mbar)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PSV (7 mbar, PEEP 5 mbar)
Number of subjects: 38
Study: 2088624

Group type: EXPERIMENTAL
Intervention: Plax prebrushing rinse
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 103
Study: 388513

Group type: EXPERIMENTAL
Intervention: Rayvist (Ioglicinate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telebrix (Ioxithalamate)
Number of subjects: 100
Study: 31050715

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (400 mg potassium daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Empty control (no pill)
Number of subjects: 42
Study: 29220533

Group type: EXPERIMENTAL
Intervention: Free Androgen Index (FAI)
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Irregular Menses (IM)
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Both FAI and IM
Number of subjects: 1422
Study: 26507858

Group type: EXPERIMENTAL
Intervention: Medical treatment with budesonide induction and azathioprine maintenance
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surgical treatment with open ileocaecal resection
Number of subjects: 36
Study: 24299928

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 200

Group type: COMPARATOR
Intervention: saline (Early-control)
Number of subjects: 200

Group type: COMPARATOR
Intervention: saline (Late-control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (Early)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (Early)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (Late)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (Late)
Number of subjects: 200
Study: 22271072

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 mg atorvastatin
Number of subjects: 100
Study: 19021129

Group type: EXPERIMENTAL
Intervention: Pre-existing knowledge of chemotherapy-associated cognitive problems
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Priming with an introduction letter mentioning cognitive complaints
Number of subjects: 261

Group type: COMPARATOR
Intervention: Neutral letter (control)
Number of subjects: 261
Study: 17326973

Group type: EXPERIMENTAL
Intervention: BiPAP ventilation combined with lung recruitment maneuvers (LRM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low tidal volume A/C ventilation (control group)
Number of subjects: 28
Study: 16355649

Group type: EXPERIMENTAL
Intervention: 0.1% fluoride (F) mucosa adhesive paste (Orabase)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo product without fluoride
Number of subjects: 6
Study: 12455727

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557

Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (ME)
Number of subjects: 557
Study: 9973871

Group type: EXPERIMENTAL
Intervention: Maximum Acceptable Weight of Lift (MAWL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum Safe Weight of Lift (MSWL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linguistic Magnitude Estimation (LME) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Load indifference concept
Number of subjects: 0
Study: 7852666

Group type: EXPERIMENTAL
Intervention: Theophylline (once daily slow-release, mean serum concentration 16 +/- 5 micrograms/ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cromolyn (2 mg administered by MDI four times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline (once daily slow-release)
Number of subjects: 16
Study: 2187372

Group type: EXPERIMENTAL
Intervention: Piritramide (n = 17)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nalbuphine (n = 20)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 54
Study: 498698

Group type: EXPERIMENTAL
Intervention: Alprenolol treatment (200 to 400 mg twice daily)
Number of subjects: 6
Study: 31815957

Group type: EXPERIMENTAL
Intervention: Narrative science messages with hero characters
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Narrative science messages with victim-to-hero characters
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Narrative science messages with victim characters
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional science messages using probability language
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional science messages using certainty language
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Narrative science messages (overall)
Number of subjects: 90
Study: 29100199

Group type: EXPERIMENTAL
Intervention: Nurse-led hypertension management model (12-week intervention)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 134
Study: 26129898

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at Tongli (HT 5) and Xuanzhong (GB 39) acupoints (ACU)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Electro-acupuncture at bilateral non-acupoints (NAP)
Number of subjects: 15
Study: 24794093

Group type: EXPERIMENTAL
Intervention: ronacaleret 100mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: ronacaleret 200mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: ronacaleret 300mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: ronacaleret 400mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: alendronate 70mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 171
Study: 23117318

Group type: EXPERIMENTAL
Intervention: Off-label closure
Number of subjects: 133

Group type: COMPARATOR
Intervention: CLOSURE I
Number of subjects: 133
Study: 19527386

Group type: EXPERIMENTAL
Intervention: 2 mg oral lycopene daily
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 159
Study: 17654408

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (CBT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined pharmacological and psychological treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combined treatment (pharmacological and psychological)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Generalized anxiety disorder treatments
Number of subjects: 24
Study: 15204794

Group type: EXPERIMENTAL
Intervention: Ultrafine particles at 50 microg/m(3)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 16
Study: 11430599

Group type: EXPERIMENTAL
Intervention: Community mental health nursing contact
Number of subjects: 274

Group type: COMPARATOR
Intervention: No community mental health nursing contact
Number of subjects: 274
Study: 9488303

Group type: EXPERIMENTAL
Intervention: Low-pressure ventriculoperitoneal shunt (LPV; 40 +/- 10 mm H2O)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Medium-pressure ventriculoperitoneal shunt (MPV; 100 +/- 10 mm H2O)
Number of subjects: 96
Study: 7836023

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3126525

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31939839

Group type: EXPERIMENTAL
Intervention: Automated management of anesthetic depth, cardiac blood flow, and protective lung ventilation using three independent controllers
Number of subjects: 90

Group type: COMPARATOR
Intervention: Manual control of anesthesia management
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Automated management
Number of subjects: 90

Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 90
Study: 29371105

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) in combination with one to two NRTIs
Number of subjects: 244

Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitors (PI/r) in combination with one to two NRTIs
Number of subjects: 244
Study: 27981552

Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional two-dimensional radiotherapy
Number of subjects: 86
Study: 25071075

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-unsaturated/low-saturated fat diet (LC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: High-unrefined carbohydrate, low-fat diet (HC)
Number of subjects: 115
Study: 22227833

Group type: EXPERIMENTAL
Intervention: Mindfulness induction task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfocused-attention induction task (Control)
Number of subjects: 0
Study: 20975464

Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine patch (active patch)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 25
Study: 17942819

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 IU BID)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16313838

Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A vaccine (H2 strain)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Vaccine coverage
Number of subjects: 220
Study: 12202710

Group type: EXPERIMENTAL
Intervention: Iopamidol with iodine concentration of 370 mg/mL (Group B)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Iopamidol with iodine concentration of 300 mg/mL (Group A)
Number of subjects: 201
Study: 10493664

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) patients (n = 13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) patients (n = 6)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rheumatoid factor positive RA patients (n = 8)
Number of subjects: 25
Study: 8670596

Group type: EXPERIMENTAL
Intervention: Aminohexane bisphosphonate 400 mg (AHBP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oestradiol valerate 2 mg and dydrogesterone 5 mg (E/D)
Number of subjects: 25
Study: 8375265

Group type: EXPERIMENTAL
Intervention: Neurothesiometer
Number of subjects: 85

Group type: COMPARATOR
Intervention: Biothesiometer
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 85
Study: 2872795

Group type: EXPERIMENTAL
Intervention: pindolol (10 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: nadolol (80 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: acebutolol (400 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control values
Number of subjects: 13
Study: 30176543

Group type: EXPERIMENTAL
Intervention: KSHV seropositivity in KS positive patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: KSHV seropositivity in KS negative patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aggregate variation in EPHA2 coding region
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Variation in Pkinase-Tyr domain
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Variation in SAM domain
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: c.2254 T>C variant in Pkinase-Tyr
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: c.2990 G>T variant in SAM
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: c.2727 C>T variant in Pkinase-Tyr
Number of subjects: 150
Study: 27081036

Group type: EXPERIMENTAL
Intervention: CEpOP +/− rituximab (R) with epirubicin (70 mg/m2/dose)
Number of subjects: 398

Group type: COMPARATOR
Intervention: CHOP +/− rituximab (R) with doxorubicin (50 mg/m2/dose)
Number of subjects: 398
Study: 25352653

Group type: EXPERIMENTAL
Intervention: Insulin glargine titrated to a fasting glucose level of ≤5.3 mmol/L (≤95 mg/dL)
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Standard therapies
Number of subjects: 12537
Study: 24321804

Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg once daily
Number of subjects: 523

Group type: COMPARATOR
Intervention: Salmeterol-fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 523
Study: 21402550

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) concurrent with tuberculosis treatment for 6 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tuberculosis treatment alone
Number of subjects: 74
Study: 19892052

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 328
Study: 17143364

Group type: EXPERIMENTAL
Intervention: Epidural analgesia using 0.2% Ropivacaine (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 80
Study: 12913647

Group type: EXPERIMENTAL
Intervention: Two screws applied laterally and parallel
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bone density measurement
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 4.5‐mm cannulated screws applied parallel from the lateral direction
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Range‐of‐motion exercises producing bending stress
Number of subjects: 64
Study: 10832512

Group type: EXPERIMENTAL
Intervention: Real age of acquisition norms derived from children's naming data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word frequency and orthographic neighbourhood size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imageability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characteristics of the word's initial phoneme
Number of subjects: 0
Study: 8522796

Group type: EXPERIMENTAL
Intervention: Training courses educating workers on proper lifting techniques
Number of subjects: 40
Study: 2039205

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (400 mg twice a day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Parenteral antibiotics (cefazolin, 1.0 g intravenously every 8 h, or ceftazidime, 2.0 g intravenously every 12 h)
Number of subjects: 33
Study: 6753642

Group type: EXPERIMENTAL
Intervention: Thiopental, 15 mg/kg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Diazepam (control)
Number of subjects: 204
Study: 31257453

Group type: EXPERIMENTAL
Intervention: ETN 50 mg plus MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ETN 25 mg plus MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-/reduced-dose combination therapy (ETN 50 mg or 25 mg plus MTX)
Number of subjects: 0
Study: 30996038

Group type: EXPERIMENTAL
Intervention: Quality Improvement Knowledge Application Tool Revised (QIKAT-R) scoring by six faculty raters (two with QI expertise, four without)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Raters with QI expertise
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Raters without QI expertise
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Three raters scoring six scenarios or two raters scoring eight scenarios
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Generalizability (G) study
Number of subjects: 28
Study: 28166757

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 24
Study: 26091924

Group type: EXPERIMENTAL
Intervention: Four sessions of 20-30 minutes of smoking-cessation counseling
Number of subjects: 500

Group type: COMPARATOR
Intervention: No additional counseling (Control)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 500